Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 10, 2024, titled "Zydus receives final approval from USFDA for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg".
Press Release Oct 10 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Paliperidone Extended-Release Tablets in various dosages. These tablets are used for treating schizophrenia and schizoaffective disorder. The production will take place at the company's manufacturing site in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 02 2024
- Press Release Oct 01 2024
- Press Release Sep 28 2024
- Press Release Sep 27 2024
- Press Release Sep 13 2024
Later from Zydus Lifesciences
- Press Release Oct 14 2024
- Press Release Oct 17 2024
- Press Release Oct 23 2024
- Press Release Nov 12 2024
- Press Release Dec 19 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences